Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Exelixis, Inc. - Common Stock (NQ:EXEL)

46.21 -2.49 (-5.11%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exelixis, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis (EXEL) Q1 2026 Earnings Transcript ↗
Exelixis (EXEL) Q1 2026 Earnings Transcript 
Via The Motley Fool
Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum ↗
Via Chartmill
News headline image
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC ↗
Via Chartmill
Exelixis Inc. (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case ↗
Via Chartmill
Exelixis Inc. (NASDAQ:EXEL) Stands Out as a Quality Investing Candidate ↗
Via Chartmill
News headline image
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist ↗
These companies boast significant upside potential. 
Via The Motley Fool
News headline image
Exelixis: A Strong Contender in the Cancer Drug Market ↗
Could Exelixis be the next big player in cancer treatment? Join us as we explore its potential and the risks involved in this exciting investment opportunity. 
Via The Motley Fool
News headline image
The Best Healthcare Stocks to Buy With $50 Right Now ↗
Even on a budget, you can get quality stocks. 
Via The Motley Fool
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue ↗
Via Chartmill
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity ↗
Via Chartmill
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
Via Chartmill
News headline image
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade ↗
The U.S.-based biotech specializes in treating cancers with small molecules, antibody-drug conjugates, and other biotherapeutics. 
Via The Motley Fool
Topics Lawsuit
News headline image
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 ↗
The stock is coming off a strong year. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis Reports Solid Earnings—Are New Highs Back on the Table? ↗
Via MarketBeat
EXELIXIS INC (NASDAQ:EXEL) Presents a High-Growth Momentum and Technical Breakout Opportunity ↗
Via Chartmill
News headline image
Exelixis (EXEL) Q4 2025 Earnings Call Transcript ↗
Exelixis (EXEL) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
2 Stocks That Could Soar This Year ↗
These innovative biotechs could have plenty of upside ahead. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
From Exelixis, Inc.
Via Business Wire
News headline image
2 Healthcare Stocks to Buy for 2026 and Beyond ↗
These could be the next biotech giants. 
Via The Motley Fool
News headline image
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
From Exelixis, Inc.
Via Business Wire
News headline image
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
From Exelixis, Inc.
Via Business Wire
News headline image
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Fundamentals with Bullish Technical Setup ↗
EXELIXIS INC (EXEL) combines strong fundamentals with a bullish technical setup. Its robust earnings growth, zero debt, and accelerating EPS align with a stock poised for a potential breakout. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.